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Abstract
Background: Genital herpes is one of the most prevalent sexually-transmitted diseases, and
accounts for a substantial morbidity. Genital herpes puts newborns at risk for very severe disease
and also increases the risk of horizontal HIV transmission. It thus stands as an important public
health problem. The recent availability of type-specific gG-based assays detecting IgG against HSV-
1 and HSV-2 allows to establish the prevalence of each subtype. Worldwide, few data have been
published regarding the seroprevalence in general populations of HSV-2, the major causative agent
for genital herpes, while no data exist regarding the Swiss population.
Methods: To evaluate the prevalence of IgG antibodies against HSV-1 and HSV-2 in Switzerland,
we used a population-based serum repository from a health examination survey conducted in the
Western and Southern area of Switzerland in 1992–93. A total of 3,120 sera were analysed by type-
specific gG-based ELISA and seroprevalence was correlated with available volunteers
characteristics by logistic regression.
Results: Overall, seroprevalence rates were 80.0 ± 0.9% (SE, 95% CI: 78.1–81.8) for HSV-1 and
19.3 ± 0.9% (SE, 95% CI: 17.6–21.1) for HSV-2 in adults 35–64 year old. HSV-1 and HSV-2
seroprevalence increased with age, with a peak HSV-2 seroprevalence in elderly gentlemen,
possibly a seroarcheological evidence of sexually transmitted disease epidemics during World War
II. Risk factors for HSV-2 infection included female sex, marital status other than married, and size
of town of residence larger than 1500 inhabitants. Unexpectedly and conversely to HSV-1, HSV-2
seroprevalence increased with educational level. HSV-2 infection was less prevalent among HSV-1
infected individuals when compared to HSV-1 uninfected individuals. This effect was most apparent
among women at high risk for HSV-2 infection.
Conclusions: Our data demonstrate that by the early nineties, HSV-2 had spread quite largely in
the Swiss population. However, the epidemiology of HSV-2 in Switzerland presents paradoxical
characteristics, e.g. positive correlation with education level, that have not been observed
elsewhere.
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Background
While Herpes simplex virus type 1 (HSV-1) is a virus trans-
mitted in casual contacts during childhood and in sexual
contacts, leading to very high prevalence rate, HSV-2 is
mostly transmitted sexually to cause genital herpes [1].
HSV-2 seroprevalence ranges from a few percent to 80%
depending on risk factors such as age, sexual promiscuity,
race and socio-economic level [1-3]. Up to half of primary
genital herpes episodes are caused by HSV-1, especially in
some European countries such as Great Britain, Scandina-
via, and Switzerland [4-8]. However HSV-2 is more prone
to cause frequent recurrence of genital symptoms [9,10] as
well as asymptomatic recurrences compared to HSV-1,
[11,12] leading to the majority of transmission events
[13]. Hence, HSV-2 remains the major player in genital
herpes.
As a cause for substantial suffering due to recurrent clini-
cal herpes [9], for catastrophic neonatal infection [14] and
as a cofactor favoring HIV infection [15], the public health
significance of genital herpes cannot be overestimated.
The most recent data available in the United States dem-
onstrate a 30% increase of HSV-2 seroprevalence as docu-
mented by NHANES II and III population surveys (1976–
80 and 1988–94 respectively) over a 12 year period [16].
Considering the role of asymptomatic transmission, the
frequency of unrecognised HSV-2 genital infection [16],
the recent availability of type-specific serologic assays
[17,18], and the absence of an efficacious prophylactic
vaccine [19], it comes as no surprise that in the US, pro-
posals for an aggressive management of genital herpes
have been made with the goal of interrupting genital her-
pes transmission. These proposals include mass screening,
identification of asymptomatic carriers, and prophylactic
treatment to prevent shedding [20,21].
However, such a rise in HSV-2 seroprevalence has not
been invariably observed in all locations [22,23]. In addi-
tion, seroprevalence rates in general populations vary
quite dramatically, for instance from about 4% in the
Spanish [24] and British [5] populations, to 15.6% in the
French population [25] and up to 31% in rural Tanzania
[26]. Even more dramatic variations of HSV-2 seropreva-
lence are observed according to established risk factors:
age, sexual activity, socio-economic and racial back-
ground [2]. Thus, the estimation of the burden of HSV-2
infection in a particular region should be based on a ran-
dom sample of its population, which may then serve as
the basis for the evaluation of the need and the design of
public health measures against the propagation of HSV-2
[16].
Regarding Switzerland, the only available data were pro-
vided by a study involving 151 low risk adult volunteers
(aged 20–49) from a single city, demonstrating a preva-
lence of HSV-2 of 11%, and suggesting that the overall
prevalence in the Swiss general population might be high
[27]. These results stressed the need for a more accurate
estimation of this disease prevalence in our country.
The MONICA serum repository [28] was collected in
1992–3 in the framework of a population survey on cardi-
ovascular risk factors conducted in two regions of Switzer-
land. As such, this repository offered the opportunity to
estimate the prevalence rates of HSV-1 and HSV-2 infec-
tion in the Swiss adult population in the early nineties
and to analyse these rates with respect to demographic
and health-related variables.
Methods
Study populations and sampling procedure
The serum repository results from the third population-
based health examination survey conducted in Switzer-
land within the framework of the multicenter WHO-
MONICA (MONItoring trends and determinants in CAr-
diovascular disease) project in 1992–3 [28]. The survey
was based on a random sample of the adult resident pop-
ulation of two Swiss regions, composed of the cantons of
Vaud and Fribourg (mainly French-speaking, age range
25–74) on one hand and of the canton of Ticino (Italian-
speaking, age range: 35 to 64) on the other hand. The two-
stage sampling procedure consisted first in drawing a ran-
dom sample of communes (administrative divisions
enclosing a village or a city and its surrounding territory)
stratified by size (number of inhabitants) and, secondly in
drawing a random sample of residents in the population
files of the selected communes. The sampling fraction of
communes were 51 out of 651 in Vaud-Fribourg and 25
out of 147 in Ticino. The population samples drafted in
these two regions were of 3300 and 2000, of whom 1742
and 1510 persons respectively accepted to participate to
the survey, corresponding to overall participation rates of
53% and 76% in the two areas. The participants were
invited to attend a health examination in their commune
of residence and to complete a self-administered ques-
tionnaire about their socio-demographic characteristics,
dietary intakes, and lifestyle habits. In addition to anthro-
pometric and blood pressure measurements, a venous
blood sample was drawn from each subject for determina-
tion of blood lipid concentrations. The blood samples
were allowed to clot at room temperature, centrifuged
within two hours of harvest, and the serum transferred
and stored at -20°C.
Socio-economic indicators
Educational level was categorized in four classes accord-
ing to the highest degree the subjects had achieved and the
age at which they completed their education, i.e. i) low :
mandatory school only (age ≤ 16); ii) medium:BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
Page 3 of 12
(page number not for citation purposes)
apprenticeship (age > 16); iii) high: secondary or profes-
sional school (age > 18) and iv) very high: university (age
> 22).
Serologic testing
Samples were assayed by ELISA (HerpeSelect, Focus Tech-
nologies, Inc., Cypress, CA) for HSV-1 and HSV-2 IgG,
according to the manufacturer instructions [18,29]. All
samples with an Index Value between 0.8–1.2 (OD stand-
ardized using a reference serum set by the manufacturer to
provide a cut off value arbitrarily given the Index value of
1) were tested again using the serum supernatant after
centrifugation (15000 rpm during 5 min on a Eppendorf
5804 microfuge) and, if still undetermined, were resolved
by immunoblot (HerpeSelect 1 & 2 Immunoblot, Focus
Technologies, Inc).
Statistical Analysis
The data from the two study regions were pooled together
for the overlapping age range (35–64) to increase statisti-
cal power. Complete data from the Vaud-Fribourg region
extending to the age range 25–74 were used to analyze age
patterns of HSV prevalence. In order to account for the
regional differences in sampling fractions and participa-
tion rates in the MONICA survey, the HSV seroprevalence
estimates were weighted by sex and age so as to be repre-
sentative of the populations of the two study regions at
the time of the survey (end of 1992). All the statistical
analyses (i.e. estimation of prevalence rates and odd
ratios, calculation of confidence intervals, logistic regres-
sion) were performed using the procedures adapted to
weight survey data ("svy commands") in the Stata 6.0
(Stata Corp, College Station, TX) software.
The matching of the epidemiological data from the MON-
ICA survey with the results of the serological testing for
HSV-1 and HSV-2 antibodies allowed to analyse the prev-
alence of herpes across the different socio-demographic
strata of the Swiss population and to identify factors influ-
encing this prevalence. Variations of the seroprevalence
rates between groups according to various characteristics
(sex, age, marital status, education level, place of resi-
dence, etc) were first examined in cross-tabulations and
bivariate logistic regression models. All variables were
then entered into a multivariate logistic regression model
in order to test whether they were predictors of the HSV
status independently of each other. The contribution of a
given explanatory variable was tested by the Wald test.
A classification tree analysis [30] was performed using the
S-PLUS (StatSci, a Division of Math Soft, Seattle, USA)
software in order to define population risk categories for
HSV-2 on the basis of the different socio-demographic
factors. This technique consists in successively splitting
the whole set of subjects into increasingly homogeneous
subsets, separating as far as possible those with a positive
HSV-2 status from those with a negative HSV-2 status.
Each split is conditioned by an optimal cut-off in the lev-
els of a single factor and the process is continued as long
as it is feasible or statistically significant. Tree-based mod-
els capture interactions between factors more easily than
logistic regression models. This procedure generated sub-
sets of subjects with increasing seroprevalence rates, i.e.
reflecting different risk levels of acquiring HSV-2. Neither
HSV-1 serostatus nor sex were used as discriminating fac-
tors because we wanted to analyse sex-specific differences
in HSV-2 seroprevalence rates according to HSV-1 serosta-
tus across these risk categories.
Ethical considerations
Serum samples had been drawn from the volunteers
under a consent involving cardiovascular research but not
explicitly for assays such as Herpes simplex antibodies.
However, taking into account the potential relationship
between Herpes simplex infection and atherosclerosis, the
anonymisation of the database and the fact that the serum
samples had been drawn 9 years before performing the
study, the performance of HSV-1 and HSV-2 assays on this
serum repository was authorised by the Institutional
Review Board of the School of Medicine, CHUV,
Lausanne.
Results
Characteristics of the study population
Of the 3235 serums available in the serum repository,
3120 could be matched in the MONICA database with
one of the 3252 participants of the health examination
survey. Fifteen samples had an identification number not
corresponding to any of the participants probably because
of transcription errors. On the other hand, 132 partici-
pants had no serum sample in the repository because of
problems in serum collection (n = 107, missing values for
blood lipids as well) or serum storage (n = 25).
Prevalence of antibodies against HSV-1 and -2 infection
Overall, for the pooled data concerning adults in the age
range 35–64, the infection rate was 80.0 % for HSV-1 and
19.3 % for HSV-2 (Tables 1 and 2). Infection rate was
higher in women than in men for HSV-1 (82.7% versus
77.2 %, p = 0.004) and for HSV-2 (20.9 % and 17.7 %, p
= 0.073), but the difference was statistically significant for
HSV-1 only (Tables 1 and 2). Seroprevalence rates were
higher in the Ticino region than in the Vaud-Fribourg
region for HSV-1 (87.7 % versus 77.0%, p < 0.001), as was
HSV-2 prevalence (20.5% versus 18.9 %, p = 0.309), but
statistical significance was reached for HSV-1 for both gen-
ders and for HSV-2 for females only (see also Table 5,
multivariate analysis).BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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Table 1: Seroprevalence of HSV-1 and HSV-2 according to various predictors in men aged 35–64, 1992–3, Vaud-Fribourg, Ticino
HSV-1 HSV-2
n Rate ± SE (95% CI) Odds Ratio 
(95% CI)
P value Rate ± SE (95% CI) Odds Ratio 
(95% CI)
P value
Region
Vaud-Fribourga 541 73.5 ± 1.9% (69.8–77.2) 1.00 (---) --- 18.1 ± 1.7% (14.9–21.4) 1.00 (---) ---
Ticino 693 87.0 ± 1.3% (84.5–89.5) 2.42 (1.81–3.24) <0.001 16.6 ± 1.4% (13.8–19.4) 0.90 (0.67–1.21) 0.487
Age group
35–44 479 70.8 ± 2.4% (66.0–75.5) 0.58 (0.34–0.83) 0.003 18.1 ± 2.0% (14.1–22.1) 1.01 (0.68–1.50) 0.956
45–54a 433 80.8 ± 2.3% (76.4–85.2) 1.00 (---) --- 17.9 ± 2.1% (13.7–22.1) 1.00 (---) ---
55–64 322 82.3 ± 2.6% (77.2–87.3) 1.10 (0.70–1.73) 0.669 16.8 ± 2.5% (12.0–21.6) 0.92 (0.59–1.45) 0.730
Marital status
Single 116 62.4 ± 5.5% (51.5–73.2) 0.45 (0.27–0.74) 0.002 21.5 ± 4.6% (12.4–30.6) 1.40 (0.79–2.49) 0.244
Marrieda 1021 78.6 ± 1.5% (75.6–81.6) 1.00 (---) --- 16.3 ± 1.3% (13.7–18.9) 1.00 (---) ---
Sep/divorced 86 76.7 ± 5.4% (66.2–87.2) 0.89 (0.48–1.65) 0.719 24.8 ± 5.3% (14.4–35.3) 1.69 (0.94–3.06) 0.081
Widowed 11 78.6 ± 15.2% (48.9–100.0) 1.00 (0.17–5.88) 0.997 54.2 ± 17.3% (20.3–88.1) 6.07 (1.53–24.11) 0.011
Educational level
Low 308 89.3 ± 2.2% (84.9–93.6) 2.56 (1.52–4.19) <0.001 17.2 ± 2.6% (12.1–22.4) 1.19 (0.77–1.85) 0.431
Mediuma 639 76.7 ± 2.0% (72.8–80.6) 1.00 (---) --- 14.9 ± 1.6% (11.7–18.0) 1.00 (---) ---
High 140 67.3 ± 4.4% (58.6–75.9) 0.62 (0.40–0.98) 0.040 21.7 ± 3.8% (14.2–29.1) 1.58 (0.95–2.63) 0.076
Very high 143 67.4 ± 4.6% (58.4–76.4) 0.63 (0.39–1.00) 0.050 26.0 ± 4.3% (17.6–34.3) 2.01 (1.21–3.32) 0.007
Size of commune
<1500 454 78.7 ± 2.4% (74.1–83.3) 1.14 (0.78–1.68) 0.485 15.2 ± 2.0% (11.3–19.2) 0.76 (0.50–1.14) 0.181
1500–10'000a 454 76.3 ± 2.4% (71.6–81.1) 1.00 (---) --- 19.2 ± 2.2% (15.0–23.5) 1.00 (---) ---
>10'000 326 76.7 ± 2.6% (71.5–81.8) 1.01 (0.69–1.50) 0.941 18.6 ± 2.4% (13.9–23.3) 0.96 (0.63–1.45) 0.844
HSV-1-infected
Noa 234 21.2 ± 2.9% (15.5–26.9) 1.00 (---) ---
Yes 1000 16.7 ± 1.4% (13.9–19.4) 0.74 (0.50–1.11) 0.143
Total 1234 77.2 ± 1.4% (74.5–80.0) --- --- 17.7 ± 1.3% (15.2–20.2) --- ---
a reference strata for the logistic analysis
Table 2: Seroprevalence of HSV-1 and HSV-2 according to various predictors in women aged 35–64, 1992–3, Vaud-Fribourg, Ticino
HSV-1 HSV-2
n Rate ± SE (95% CI) Odds Ratio 
(95% CI)
P value Rate ± SE (95% CI) Odds Ratio 
(95% CI)
P value
Region
Vaud-Fribourga 565 80.4 ± 1.7% (77.2–83.7) 1.00 (---) --- 19.6 ± 1.7% (16.3–22.9) 1.00 (---) ---
Ticino 743 88.4 ± 1.2% (86.1–90.7) 1.86 (1.37–2.53) <0.001 24.3 ± 1.6% (21.2–27.4) 1.31 (1.00–1.72) 0.047
Age group
35–44 490 78.8 ± 2.1% (74.7–83.0) 0.72 (0.49–1.06) 0.097 19.5 ± 2.0% (15.7–23.3) 0.83 (0.58–1.18) 0.292
45–54a 472 83.8 ± 2.0% (79.8–87.8) 1.00 (---) --- 22.6 ± 2.2% (18.2–27.0) 1.00 (---) ---
55–64 346 86.7 ± 2.3% (82.2–91.3) 1.26 (0.77–2.07) 0.347 20.9 ± 2.6% (15.8–26.0) 0.90 (0.61–1.34) 0.609
Marital status
Single 106 81.1 ± 4.7% (72.0–90.3) 0.87 (0.46–1.63) 0.658 27.3 ± 5.3% (16.9–37.8) 1.77 (1.02–3.10) 0.044
Marrieda 984 83.2 ± 1.4% (80.5–86.0) 1.00 (---) --- 17.5 ± 1.4% (14.8–20.2) 1.00 (---) ---BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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Sep/divorced 142 77.2 ± 4.1% (69.1–85.2) 0.68 (0.41–1.12) 0.131 35.1 ± 4.5% (26.3–43.9) 2.55 (1.66–3.92) <0.001
Widowed 76 90.0 ± 4.1% (81.9–98.0) 1.81 (0.72–4.53) 0.205 28.6 ± 6.1% (16.7–40.5) 1.89 (1.02–3.48) 0.042
Educational level
Low 471 89.2 ± 1.8% (85.6–92.7) 1.75 (1.13–2.72) 0.012 16.5 ± 2.0% (12.6–20.4) 0.65 (0.45–0.92) 0.014
Mediuma 637 82.4 ± 1.8% (78.9–85.9) 1.00 (---) --- 23.4 ± 1.9% (19.7–27.2) 1.00 (---) ---
High 138 74.4 ± 4.1% (66.3–82.5) 0.62 (0.38–1.01) 0.055 23.6 ± 4.0% (15.7–31.4) 1.01 (0.62–1.64) 0.974
Very high 59 63.0 ± 7.1% (49.1–76.9) 0.36 (0.19–0.69) 0.002 18.2 ± 4.9% (8.6–27.8) 0.73 (0.37–1.43) 0.356
Size of commune
<1500 437 80.3 ± 2.3% (75.8–84.8) 0.54 (0.35–0.84) 0.006 15.7 ± 2.0% (11.8–19.5) 0.64 (0.44–0.93) 0.020
1500–10'000a 495 88.2 ± 1.7% (84.9–91.6) 1.00 (---) --- 22.5 ± 2.1% (18.3–26.7) 1.00 (---) ---
>10'000 376 79.1 ± 2.4% (74.4–83.8) 0.50 (0.33–0.78) 0.002 24.1 ± 2.5% (19.3–29.0) 1.09 (0.76–1.56) 0.629
HSV-1-infected
Noa 197 29.0 ± 3.6% (21.9–36.0) 1.00 (---) ---
Yes 1111 19.3 ± 1.4% (16.6–21.9) 0.59 (0.40–0.86) 0.006
Total 1308 82.7 ± 1.2% (80.2–85.1) --- --- 20.9 ± 1.3% (18.4–23.5) --- ---
a reference strata for the logistic analysis
Table 3: Age-dependent seroprevalence of HSV-1 and HSV-2, Vaud-Fribourg, 1992–3, Men
HSV-1 HSV-2
Age group n Rate seropositive 
(±SE, 95% CI)
Odds Ratio 
(95%CI)
P value Rate seropositive 
(±SE, 95% CI))
Odds Ratio 
(95%CI)
P value
25–34 189 58.2 ± 3.6% (51.2–65.3) 0.39 (0.25–0.62) <0.001 10.6 ± 2.2% (6.2–15.0) 0.53 (0.29–0.96) 0.037
35–44 223 66.4 ± 3.2% (60.2–72.6) 0.56 (0.36–0.87) 0.010 18.4 ± 2.6% (13.3–23.5) 1.01 (0.61–1.67) 0.978
45–54a 186 78.0 ± 3.0% (72.0–83.9) 1.00 (--) -- 18.3 ± 2.8% (12.7–23.8) 1.00 (---) ---
55–64 132 78.8 ± 3.6% (71.8–85.8) 1.05 (0.61–1.81) 0.860 17.4 ± 3.3% (10.9–23.9) 0.94 (0.52–1.70) 0.845
65–74 85 78.8 ± 4.5% (70.1–87.6) 1.05 (0.56–1.97) 0.873 29.4 ± 5.0% (19.7–39.2) 1.86 (1.02–3.40) 0.042
Total 815 69.9 ± 1.6% (66.8–73.0) --- --- 17.3% ± 1.3% (14.7–19.9) --- ---
areference strata for the logistic analysis
Table 4: Age-dependent seroprevalence of HSV-1 and HSV-2, Vaud-Fribourg, 1992–3, Women
HSV-1 HSV-2
Age group n Rate seropositive 
(±SE, 95% CI)
Odds Ratio 
(95%CI)
P value Rate seropositive 
(±SE, 95% CI)
Odds Ratio 
(95%CI)
P value
25–34 204 69.1 ± 3.2% (62.8–75.5) 0.54 (0.35–0.85) 0.008 12.2 ± 2.3% (7.7–16.8) 0.47 (0.28–0.81) 0.006
35–44 237 77.2 ± 2.7% (71.9–82.6) 0.81 (0.51–1.29) 0.376 17.3 ± 2.5% (12.5–22.1) 0.71 (0.44–1.14) 0.154
45–54a 202 80.7 ± 2.8% (75.2–86.1) 1.00 (---) --- 22.8 ± 3.0% (17.0–28.6) 1.00 (---) ---
55–64 126 84.9 ± 3.2% (78.6–91.2) 1.35 (0.74–2.46) 0.332 19.0 ± 3.5% (12.2–25.9) 0.80 (0.46–1.39) 0.426
65–74 100 84.0 ± 3.7% (76.8–91.2) 1.26 (0.66–2.39) 0.486 17.0 ± 3.8% (9.6–24.4%) 0.69 (0.37–1.29) 0.249
Total 869 77.9 ± 1.4% (75.2–80.7) --- --- 17.3 ± 1.3% (14.8–19.8) --- ---
areference strata for the logistic analysis
Table 2: Seroprevalence of HSV-1 and HSV-2 according to various predictors in women aged 35–64, 1992–3, Vaud-Fribourg, Ticino BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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HSV seroprevalence and variables other than age
For sociodemographic variables other than age, the asso-
ciation with HSV infection was analyzed using the pooled
data of both regions within the age range 35–64. Sex-spe-
cific seroprevalence rates and unadjusted odds-ratios are
shown in Tables 1 and 2. Adjusted odds ratios, 95%
confidence intervals and p values resulting from multivar-
iate logistic regression models of HSV-2 seroprevalence
are shown on Table 5.
HSV seroprevalence and marital status
Marital status was associated with HSV infection in both
sexes. In males, a lower HSV-2 seroprevalence was
observed in married subjects compared to all other cate-
gories, significantly so in widowed subjects as compared
to married subjects (Table 1). In females, HSV-2 seroprev-
alence was significantly higher in all categories (single,
separated/divorced, or widowed) as compared to married
subjects (Table 2). This observation was supported by the
multivariate analysis (Table 5, p = 0.013 and 0.0004 for
males and females respectively by the Wald test for the
overall contribution of the marital status variable).
HSV seroprevalence and socio-economic status
Several socio-economic variables were collected in the
MONICA survey: level of education, economic sector,
employment grade and job qualification level. While sim-
ilar trends in HSV seroprevalence rates were observed
according to all these variables, the level of education
showed the strongest association and was therefore
selected for the present analysis.
The seroprevalence of HSV-1 decreased with increasing
level of education in both genders (Tables 1 and 2). In
contrast, the seroprevalence of HSV-2 increased signifi-
cantly with increasing level of education (Tables 1 and 2).
In males, the odds of being infected by HSV-2 were higher
in subjects with high or very high education levels (see
definition in material and methods) compared with sub-
jects with low or medium education levels (Table 1),
while in females, subjects with a low education level stood
out with a low HSV-2 seroprevalence as compared with all
higher education level subjects (Table 2). Again, this
observation withstood the test of the multivariate analysis
for males, and nearly so for females (Table 5, p = 0.045
and 0.064 for males and females respectively by the Wald
test for the overall contribution of the education level
variable).
HSV seroprevalence and size of place of residence
As the two-stage sampling procedure of the MONICA sur-
vey consisted first in drawing a random sample of com-
munes (see definition under method section) stratified
according to their size, we could analyse the association
between commune size and HSV seroprevalence. As seen
in Tables 1 and 2, HSV-2 seroprevalence was lower among
residents from small communes (<1500 inhabitants),
when compared to residents from larger towns. This trend
for a lower odd ratio of being infected by HSV-2 was sig-
nificant among females. Again, this conclusion was sup-
ported by the multivariate analysis (Table 5, p = 0.53 and
0.02 for males and females respectively by the Wald test
for the overall contribution of the place of residence
variable).
Interaction between HSV-1 and HSV-2 infection
HSV-1-seropositive individuals had a lower HSV-2 sero-
prevalence rate compared to HSV-1-uninfected subjects,
and this difference was statistically significant in women
and of borderline significance in men (Tables 1 and 2).
The inverse association between HSV-1 and HSV-2 sero-
logical status persisted after adjustment for age and the
other sociodemographic variables in females (Table 5, p =
0.30 and 0.006 for males and females respectively by the
Wald test for the overall contribution of the HSV-1
serostatus variable). The potential role of sex and HSV-1
status in protection against HSV-2 transmission was more
closely examined in population risk groups for HSV-2
infection defined by classification tree analysis (see meth-
ods). Young adults 25 to 34 years old and living alone
formed the lowest risk group (HSV-2 seroprevalence:
3.9%) and those living with a partner formed the second
lowest (13.3%). The highest risk group comprised the
adults aged 35 years and more who were separated,
divorced or widowed (31.6%) while those single or mar-
ried had an intermediate risk depending of their educa-
tional level (less than high: 17.0%; high or very high:
23.6%). Figure 1 shows the HSV-2 seroprevalence rate in
these five groups according to sex and HSV-1 serostatus.
The protective effect of HSV-1 infection against HSV-2 was
mostly contributed by women in the high risk group for
HSV-2 infection with an odds ratio of 0.37 (95% confi-
dence interval 0.19–0.75; p = 0.005).
HSV seroprevalence in pregnant women
Women in the MONICA study were asked whether they
had been pregnant within the twelve months before par-
ticipating to the study. Among those 55 answering that
they had been, 72.7% were seropositive for HSV-1 and
9.1% for HSV-2.
HSV prevalence and age
Since a larger age range of participants was sampled in the
Vaud-Fribourg region, the relationship between age and
HSV seroprevalence was analysed in detail in this region.
Of note, similar age patterns in HSV-1 and -2 prevalence
were observed in the Ticino sample from age 35 to 64. As
shown in Tables 3 and 4, the prevalence of HSV-1 infec-
tion was high even among the youngest subjects (25–34
year old, 58.2% among males and 69.1 % amongBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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females). This prevalence increased with age. The preva-
lence of HSV-2 was respectively 10.6% among males and
12.2 % among females 25–34 year old. In middle-aged
adults (35–64 years old) of both gender, the HSV-2 sero-
prevalence rates reached a plateau at 18–20%. In the
elderly (65–74 years old), men had a significantly higher
seroprevalence rate than their middle-aged counterparts.
Discussion
In the present study, data regarding the prevalence of
HSV-1 and, more importantly HSV-2, have been obtained
for the first time from a multistage probability sample of
the general population in two regions of Switzerland.
Generating a population-based repository is a complex
and costly task; however only such a repository provides
information on the prevalence and allows to analyse pre-
dictors for infection in the general population. Indeed,
few studies of HSV seroprevalence have used such
repositories [16,25,26]. Most of the published
seroprevalence data have been from selected groups of
populations [2].
The present serum repository was harvested in the frame-
work of a population-based study of cardiovascular risk
factors: as such, our study has several limitations. First, the
low participation rate (53%) of the population survey in
the Vaud-Fribourg region challenges the representative-
ness of the data. While lower than participation in a sim-
ilar major study, the availability of the majority of the sera
led to 51% of the sample having a serostatus determined,
HSV-2 seroprevalence by sex and HSV-1 serostatus in the Swiss population across five strata from the lowest to the highest  risk for HSV-2 infection defined by decision analysis using predictors identified by logistic analysis (Aged less than 35, living  alone; aged less than 35 living with a partner; single or married with a low level of education; single or married with a high level  of education; divorced or separated or widowed) Figure 1
HSV-2 seroprevalence by sex and HSV-1 serostatus in the Swiss population across five strata from the lowest to the highest 
risk for HSV-2 infection defined by decision analysis using predictors identified by logistic analysis (Aged less than 35, living 
alone; aged less than 35 living with a partner; single or married with a low level of education; single or married with a high level 
of education; divorced or separated or widowed)
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versus 60.2% in the NHANES III study [16]. In addition,
the results have been weighted by sex and age to adjust for
participation bias. Second, because of its limited age range
(25 to 74), the study does not provide information about
the HSV prevalence rates among children and adolescents.
Third, the serum repository was harvested during a single
cross-sectional survey in the early nineties and time trends
in HSV seroprevalence in Switzerland cannot be moni-
tored using these data. Fourth, sampling occurred in only
two (French and Italian-speaking) regions. Recent data
from the Zurich area using selected samples of population
however seem to indicate a similar high HSV-2 seropreva-
lence in the German-speaking area (S. Lautenschlager,
personal communication). Finally, the questionnaire did
not include questions regarding sexual behaviour, pre-
cluding HSV prevalence analysis for these variables.
Nevertheless, our study provides data interesting to com-
pare in particular with HSV-1 and -2 seroprevalence data
gathered at about the same time in the US [16,31]. The fig-
ures obtained indicate that HSV-1 seroprevalence is very
similar in Switzerland and in the US, and varies similarly
according to age, and socio-economic variables. HSV-2
seroprevalence was somewhat lower in Switzerland, with
a very similar effect of age on prevalence. In particular, in
both populations, HSV-2 seroprevalence plateaus among
middle age subjects from the third to the sixth decade of
life. Interestingly, we observed a significant peak HSV-2
seroprevalence among elderly men (65–74 year old).
These are subjects who were 15 to 24 year old during sec-
ond world war (in 1942–43). Although we are unaware of
any report of epidemics of sexually transmitted diseases in
Switzerland at that time, it is well know that social disrup-
tion related to the war led to epidemics of STD elsewhere
in the world, even in areas not directly involved in the
conflict [32]. We therefore wonder whether this observa-
tion is a sero-archeological testimony of past changes in
STD epidemiology, i.e. increased STD transmission in
Table 5: Multivariate logistic analysis of the risk of HSV-2 infection in males and females, 1992–3, Vaud-Fribou rg, Ticino
males females
Odds Ratio 95% CI P value Odds Ratio 95% CI P value
Region
Vaud-Fribourga 1.00 --- --- 1.00 --- ---
Ticino 0.97 0.70–1.34 0.85 1.53 1.14–2.05 0.004
Age group
35–44 0.96 0.64–1.43 0.83 0.79 0.55–1.12 0.19
45–54a 1.00 --- --- 1.00 --- ---
55–64 0.89 0.56–1.40 0.61 0.87 0.57–1.32 0.52
Marital status
Single 1.24 0.69–2.23 0.48 1.57 0.89–2.79 0.12
Marrieda 1.00 --- --- 1.00 --- ---
Sep/divorced 1.70 0.93–3.13 0.08 2.35 1.52–3.63 <0.001
Widowed 7.23 1.85–28.3 0.005 2.10 1.08–4.06 0.027
Educational level
Low 1.25 0.80–1.97 0.329 0.63 0.44–0.91 0.015
Mediuma 1.00 --- --- 1.00 --- ---
High 1.56 0.94–2.61 0.08 0.99 0.61–1.63 0.98
Very high 2.01 1.19–3.39 0.009 0.63 0.29–1.33 0.22
Size of commune
<1500 0.79 0.52–1.20 0.27 0.61 0.41–0.91 0.015
1500–10'000a 1.00 --- --- 1.00 --- ---
>10'000 0.93 0.61–1.44 0.77 1.03 0.71–1.51 0.86
HSV-1-infected
Noa 1.00 --- --- 1.00 --- ---
Yes 0.79 0.52–1.23 0.30 0.58 0.39–0.85 0.006
a reference strata for the logistic analysis. Odds ratios for a given variable are adjusted for the other variables in the TableBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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Swiss males fifty years before the survey was conducted.
Why this would not be paralleled by a higher HSV-2 sero-
prevalence in females is unknown. However, this
epidemic might have been preferentially transmitted to
young males by a small core group of promiscuous
females (e.g. prostitutes), which would be in number
negligible compared to the general population. These
females might also have been older than their sexual
mates.
While HSV-2 seroprevalence was similar in the US in met-
ropolitan and non urban counties [16], our study allowed
to analyse the relationship between the size of the com-
munity (commune) of residence and HSV-2 seropositivity
probably with a better resolution, and indeed demon-
strates that at the time of the survey, individuals, and par-
ticularly women, living in rural areas and villages had a
significantly reduced risk of HSV-2 infection.
The marital status had a similar influence on HSV-2 sero-
prevalence in the US and in Switzerland, suggesting that
being separated/divorced or widowed is associated with a
higher risk of infection. In contrast, the relationship
between the socio-economic status, as expressed here by
the education level, and HSV-2 seropositivity was oppo-
site particularly in women in the Switzerland compared to
the US, [16,33] and indeed to other countries [26,34].
This contrasts also with the inverse correlation between
HSV-1 seroprevalence and socio-economic level in our
study, a well known worldwide observation [2]. In the
absence of information regarding determinants of expo-
sure to sexually transmitted diseases in our database, we
attempted to explain this paradoxical relationship, by
resorting to data in an unrelated study performed in
1992–94 and assessing sexual behaviour in relation with
sociodemographic variables in the same area (Western
Switzerland) where our study was performed [35]. By re-
analysing these data, we could evidence a positive correla-
tion between education level and the life time number of
sex partners which almost reached significance in female
subjects. However, no such correlation was observed in
males. In fact HSV-2 seroprevalence in our study is the
result of transmission events that occurred over several
decades before the serum collection. We interpret this
observation as consistent with the hypothesis that in Swit-
zerland, the liberal changes in the sexual behaviour that
occurred during these decades have had more of an
impact on the higher social strata. Interestingly, a similar
trend, though not statistically significant, was recently
described in a similar population-based study in France
[25].
There is a continuum in the extent to which the spread of
various STDs require very high rates of partner change and
unprotected exposure to new partners [36]. Those that
appear not to require high rates of partner change include
HSV and HPV, are less concentrated in core groups, com-
pared to bacterial STDs and more widely spread across a
variety of socio-economic categories in populations [36].
Our data demonstrate that HSV-2 transmission is not only
spread across a large variety of socio-economic categories,
but, under given conditions, can concentrate among strata
of populations usually at lower risk for STDs. The poten-
tial impact of our observation for the design of future pre-
vention campaigns against STDs remains to be evaluated.
Among women who had been pregnant within twelve
months before participating to the study, a little more
than 9% were seropositive for HSV-2. They were thus at
risk for genital herpes reactivation which carries a moder-
ate risk for neonatal herpes [37]. On the other hand, close
to 30% were seronegative for HSV-1, (the cause for about
50% of primary genital infections in Switzerland [6] and
in Europe [7,38]) and 90% were seronegative for HSV-2.
These were thus at risk for a primary infection with the
corresponding virus, a condition associated with a very
high risk of neonatal herpes [37]. Our data thus provide
an estimate of the population at risk for transmitting her-
pes to neonates. The actual incidence of neonatal herpes,
which obviously varies with the rate for acquiring genital
herpes during the third trimester of the pregnancy, a rate
unknown in Switzerland, is currently determined in a
countrywide prospective surveillance for neonatal herpes
in the framework of the Swiss Pediatric Surveillance Unit.
Interaction between HSV-1 and HSV-2 remains a conten-
tious issue. While it is generally admitted that patients
with antibodies against HSV-1 and -2 are less likely to
report a symptomatic genital herpes compared to patients
with antibodies against HSV-2 only [4,31,39], it is less
clear whether antecedent HSV-1 infection can protect
against subsequent HSV-2 acquisition. On one hand,
cross-sectional studies using type-specific immunoassays
have suggested that HSV-1 afford such a protection
against subsequent HSV-2 infection, with an odd ratio of
0.7 among women attending family planning clinics [33],
0.78 in STD clinic attendees in California [40] and of 0.37
among Mexican prostitutes [41]. On the other hand, Xu et
al. recently did not detect any significant protection nei-
ther in males nor in females in the general US population
[31]. Similar data were reported recently in a population
of Dutch STD clinic attendees, but the effect of HSV-1 on
HSV-2 seropositivity rate was not analysed by sex [42].
This question has also been examined in the framework of
prospective studies measuring the rate of HSV-2 transmis-
sion among serodiscordant couples. For instance, Mertz et
al. [13] and Bryson et al. [43] evidenced a reduced rate of
acquisition of HSV-2 infection in partners with previous
HSV-1 infection as compared to HSV-1-uninfected part-
ners. In contrast, no such protective effect of HSV-1 infec-BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/10
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tion was observed in pregnant women followed up
prospectively [44] nor in HSV-2 seronegative sexually
active participants to vaccine trials followed up prospec-
tively [4].
As discussed recently [31], our study is admittedly not ide-
ally suited for the study of the interaction between HSV-1
and HSV-2 because the data are cross-sectional. However,
the difference in transmission mode between these two
viruses results in HSV-1 preceding HSV-2 infection in a
vast majority of cases [1], raising the possibility that
antecedent HSV-1 infection may affect the susceptibility
to, or the clinical expression of, HSV-2 infection. In the
present study, HSV-1 seropositivity, when introduced in
the multivariate logistic model, was associated with pro-
tection against HSV-2 infection, significantly so in
women. However, for a protection against an infection to
appear in a given population, this population has to be
exposed. Using a decision analysis procedure, our study
population was stratified by sex in five strata from the
lowest to highest risk of acquiring HSV-2 infection, based
on identified predictors other than HSV-1 seropositivity.
The HSV-2 seropositivity rate was most strikingly reduced
by HSV-1 seropositivity among women at the highest risk
for HSV-2 infection.
Our results are thus consistent with the hypothesis that
HSV-1 can prevent the acquisition of subsequent HSV-2
infection, and that this effect can be observed primarily
among heavily exposed individuals, i.e. women highly
exposed to HSV-2. Our observations may therefore
explain why this protective effect is not universally
observed in studies, depending on the study population
exposure to HSV-2 infection. It is interesting to speculate
why protection was observed only in women, reminiscent
of the recent observation that a gD2-based vaccine dem-
onstrated efficacy against infection limited to
women).)[45]. First, the risk of transmission is higher
from males to females than from females to males [46],
making it easier to demonstrate protection in females
than in males. Second, if protection is afforded by locally
produced antibodies, then a mucous membrane covered
by fluid containing antibodies such as the female genital
mucosa is more likely to be protected than dry skin.
In addition, it is interesting to note the recent epidemio-
logical trend for a reduced acquisition of HSV-1 during
childhood, leading to an increasing sexual transmission of
HSV-1 [5,5,42]. Therefore, assuming that HSV-1 precedes
HSV-2 infection may become less valid an assumption in
the future.
Conclusions
The present study provides a snapshot view of the epide-
miology of Herpes simplex viruses in the Western and
Southern Swiss population in the early nineties. Assuming
that the HSV-2 seroprevalence is similar throughout Swit-
zerland as supported by recent studies in the Zurich area
(S. Lautenschlager, personal communication), a projec-
tion suggests that countrywide, about 500'000 out of
2'633'000 people aged 35 to 64 in 1992 were infected by
HSV-2. Risk factors for HSV-2 infections were identified as
age, marital status (separated, divorced or widowed), res-
idence in towns of middle to large size, and paradoxically,
higher education in women. HSV-1 infection was associ-
ated with a lower HSV-2 seroprevalence particularly in
HSV-2 exposed women. These data are important for the
design of public health interventions aimed at preventing
genital herpes spread. As sexual behavior surveillance
studies have shown increased condom use without
changes in other indicators, predicting the course of HSV-
2 epidemic beyond 1992–3 is difficult. Hence, follow up
studies in Switzerland should include, in addition to sur-
veillance for neonatal herpes, a repeated population-
based study to assess any temporal trend in HSV
seroprevalence.
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